INTRODUCTION {#s1}
============

Regulation of the p53 tumor suppressor and transcriptional activator is critical for normal cellular proliferation and survival. Mdm4, a homologue of Mdm2, is a *bona fide* negative regulator of p53 \[[@R1]\]. Genetic ablation of Mdm4 results in p53-dependent early embryonic lethality in mice \[[@R2]-[@R4]\], while deletion of Mdm4 in adult mouse tissues leads to subtle activation of p53 that can be potentially harnessed for therapeutic purposes \[[@R5]\]. Mdm4 inhibits the transcriptional activity of p53 by binding to and masking its transcriptional activation domain. In addition, Mdm4 heterodimerizes with Mdm2 through its RING domain to generate an effective E3-ubiquitin ligase that degrades p53 protein during early embryogenesis \[[@R6], [@R7]\].

Overexpression and amplification of *MDM4* is a common theme associated with suppression of the p53 pathway in a range of human tumors \[[@R8]-[@R13]\]. In addition, multiple studies have highlighted the expression of *MDM4* spliced variants in different tumors types \[[@R11], [@R14]\]. One *MDM4* spliced variant, *MDM4-S* that skips exon 6 and prematurely terminates in exon 7 has been the subject of close scrutiny in recent years \[[@R15]\]. The *MDM4-S* transcript potentially encodes a truncated Mdm4 protein carrying only the N-terminal p53-binding domain along with 13 novel amino acids \[[@R16]\]. Overexpression of *MDM4-S* has been linked to poor prognosis in osteosarcoma, soft tissue sarcoma, breast cancer, glioblastoma, melanoma, and chronic lymphocytic leukemia \[[@R17]-[@R21]\]. MDM4-S lacks an internal autoinhibitory sequence \[[@R22]\] and previous overexpression studies indicated that nuclear localized MDM4-S acts as a potent inhibitor of p53 activity and thus likely functions as an oncogene \[[@R15], [@R16]\]. Recent studies however suggest that the *MDM4-S* transcript is susceptible to nonsense mediated decay and thus acts as a critical determinant of MDM4 expression in tumors with mutant p53 \[[@R17], [@R18]\]. It is not clear why tumor cells with a defective p53 pathway would require a reduction in full-length Mdm4 levels.

While the oncogenic potential of the full length Mdm4 protein has been clearly demonstrated by mouse studies \[[@R23]\], similar studies characterizing the Mdm4-S form are lacking. In the absence of prospective animal studies, it is not clear whether *Mdm4-S* overexpression is a cause or a consequence of tumorigenesis. To address this issue, a knock-in mouse was recently generated \[[@R24]\]. Unfortunately, the mouse was embryonic lethal due to excessive p53 activity. This suggests that overexpression of Mdm4-S form is not sufficient to overcome the loss of endogenous full length Mdm4. Alternatively, it is possible that loss of the C-terminus RING domain function in these mice lead to pre-natal lethality \[[@R6], [@R7]\].

We recently examined *MDM4-S* expression in B-cell chronic lymphocytic leukemia (B-CLL, a B-cell associated malignancy) patient samples. Interestingly, over 47% of patient samples overexpressed *MDM4-S* mRNA compared to normal healthy volunteer controls. To gain more insight into the role of *MDM4-S* splice variant in B-cell malignancies, we generated a transgenic mouse wherein Mdm4-S overexpression was regulated by the Ig gene VH promoter along with the intronic enhancer and restricted to the B-cell lineage. This strategy prevented the early embryonic lethality of truncated Mdm4 expression and allowed us to investigate the significance of Mdm4-S overexpression in development of B-cell hematopoietic malignancies in mice. Herein, we present the results obtained with this mouse model and provide evidence that splicing of *Mdm4* is a consequence rather than a cause of tumorigenesis.

RESULTS {#s2}
=======

*MDM4-S* variant is overexpressed in B-CLL patient samples {#s2_1}
----------------------------------------------------------

Recent studies have linked *MDM4-S* overexpression to poor prognosis in human cancer \[[@R17]\]. In order to test whether the *MDM4-S* form is overexpressed in B-CLL, we carried out an initial screening of 36 unselected samples obtained from patients with newly diagnosed B-CLL prior to undergoing standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (i.e. FCR regimen) at the MD Anderson Cancer Center (Table [1](#T1){ref-type="table"}). Overall, 47% (17/36) of patient samples showed increased expression of the *MDM4* splice variant, *MDM4-S* to varying extents ranging from 2 fold to 42 fold as compared with B-cells obtained from normal healthy volunteers (Figure [1A](#F1){ref-type="fig"}). Next, we compared the expression of full length *MDM4* and the corresponding *MDM4-S/MDM4* ratio in these patient samples. The *MDM4-S/MDM4* ratio in these patients was also noticeably higher than normal controls (Figure [1B](#F1){ref-type="fig"}). Of note, during the conduction of this project a separate study from China also reported higher levels of *MDM4-S* in a larger cohort of B-CLL patients correlating with poor prognosis after FCR therapy \[[@R20]\]. Overall, these two independent reports clearly implicate *MDM4-S* overexpression in the pathogenesis of B-CLL.

###### Clinical and biological characteristics of chronic lymphocytic leukemia patients

  CLL No.   Age yrs   Sex M/F   Rai stage   B2M μg/ml   HGB g/dL   PLT x10^9^/L   WBC x10^9^/L   Absolute Lympho /μl   \% ATM deletion (FISH)   \% Deletion 13q (FISH)   \% Trisomy 12 (FISH)   \% p53 deletion (FISH)   IgVH mutational status   ZAP70   Mdm2 SNP309 rs2279744   Mdm4-S \>2-fold
  --------- --------- --------- ----------- ----------- ---------- -------------- -------------- --------------------- ------------------------ ------------------------ ---------------------- ------------------------ ------------------------ ------- ----------------------- -----------------
  1         61        M         1           3.3         11.7       205            119.2          113240                89                       0                        0                      0                        UNMUTATED                \+      TT                      No
  4         67        M         3           4           9.5        168            177.6          166944                ND                       ND                       ND                     ND                       UNMUTATED                \+      GT                      No
  6         61        M         4           4.2         16.5       50             161.6          145440                0                        0                        46                     0                        MUTATED                  \+      ND                      No
  7         50        M         4           5.3         13.6       97             45.1           39237                 61                       0                        0                      0                        UNMUTATED                \+      TT                      No
  8         55        M         2           3.2         14.6       236            63.4           53256                 0                        65.5                     0                      0                        MUTATED                  \-      GT                      No
  9         57        M         1           4.5         12.8       180            135.2          123032                0                        78                       0                      0                        UNMUTATED                \+      GT                      No
  10        59        M         3           2.7         9.8        191            137.6          125216                0                        0                        62.5                   0                        UNMUTATED                \+      GT                      No
  16        53        M         4           5.8         12.9       79             32.6           29666                 0                        0                        0                      0                        UNMUTATED                \-      GG                      No
  17        66        M         1           6.2         12.4       116            151.4          140802                94                       96.5                     0                      0                        UNMUTATED                \-      TT                      No
  21        66        M         3           3           10.9       116            252.5          242400                0                        95.5                     0                      0                        NR                       \+      GT                      No
  23        61        F         2           2.3         13.5       266            164.9          158304                95.5                     86.5                     0                      0                        UNMUTATED                \-      GT                      No
  28        65        M         2           4           12.4       116            158.5          142650                0                        69                       0                      78                       MUTATED                  ND      TT                      No
  30        62        F         0           2.6         12.2       177            153.7          144478                0                        92.5                     0                      0                        NR                       \-      TT                      No
  32        58        F         1           2.4         11.2       101            139.2          139200                0                        71                       0                      0                        MUTATED                  \-      GG                      Yes
  60        62        F         2           6.9         11.4       225            114.3          102870                0                        80.5                     0                      0                        MUTATED                  \+      GG                      Yes
  65        55        F         1           3           11.9       159            222.8          207204                0                        0                        0                      0                        UNMUTATED                \-      TT                      Yes
  67        54        F         2           2.6         15.9       201            52.2           48024                 0                        40                       0                      0                        UNMUTATED                \-      GT                      Yes
  69        63        M         4           3.4         9.6        56             5.9            5428                  10                       0                        0                      0                        UNMUTATED                \+      GT                      Yes
  73        51        F         2           1.7         13.7       140            36.3           33033                 0                        80                       0                      0                        MUTATED                  \-      TT                      Yes
  74        74        M         4           3.3         13.4       88             161.8          148856                96                       95                       0                      0                        UNMUTATED                \+      GT                      Yes
  77        60        F         4           3.2         9.9        80             120            115200                0                        73.5                     0                      0                        MUTATED                  \-      GT                      Yes
  78        73        F         2           3.1         11.4       192            177.9          167226                0                        0                        73                     0                        UNMUTATED                \+      TT                      Yes
  79        64        M         1           4.5         11.5       168            100.4          90360                 21.5                     52.5                     0                      0                        UNMUTATED                \+      TT                      Yes
  81        62        M         3           3.1         10.6       254            74.2           69748                 0                        0                        57.5                   0                        UNMUTATED                \+      GT                      No
  87        57        F         2                       12.1       129            67.1           55693                 0                        0                        53                     0                        MUTATED                  ND      TT                      Yes
  88        63        F         2           6           11.9       201            267.9          235752                ND                       ND                       ND                     ND                       UNMUTATED                \+      TT                      No
  93        44        M         4           4.2         8.9        57             31             30070                 0                        80.5                     0                      0                        MUTATED                  \-      GT                      Yes
  94        53        F         3           3.1         10.4       163            196.4          182652                0                        0                        0                      0                        UNMUTATED                \+      GT                      No
  95        50        F         1           2           12.4       193            121.3          115235                0                        89                       0                      0                        MUTATED                  ND      GT                      Yes
  96        58        F         2           4           12.5       220            221.4          210330                0                        62.5                     0                      88.5                     UNMUTATED                \-      TT                      Yes
  97        58        M         4                       9.5        15             71.5           71500                 94.5                     0                        0                      0                        UNMUTATED                \+      TT                      No
  99        58        F         3           11.4        10         131            120.5          110860                23                       12                       0                      0                        UNMUTATED                \+      TT                      Yes
  100       62        M         3           3.5         10.2       111            141            138180                0                        0                        0                      0                        MUTATED                  \-      GT                      Yes
  101       49        M         2           2.8         13.2       119            94.5           91665                 0                        92.5                     0                      65                       UNMUTATED                \+      GG                      No
  102       60        F         2           4.9         12.6       195            84.5           47320                 0                        0                        0                      0                        UNMUTATED                \+      GT                      Yes
  103       71        M         3           6           8.9        190            182.6          173470                55.5                     0                        82                     0                        UNMUTATED                \+      TT                      Yes

Abbreviations: F: female, M: male, B2M: beta 2 microglobulin, HGB: hemoglobin, PLT: platelet count, WBC: white blood cell count, absolute lympho: absolute lymphocyte count, FISH: fluorescence in situ hybridization, ZAP70: Zeta Chain of T Cell Receptor Associated Protein Kinase 70kDa, IgVH: heavy chain of the immunoglobulin gene, +: positive, -- : negative, ND: not determined.

![***Mdm4-S*** is overexpressed in B-CLL. **A**. Real-time PCR showing *MDM4-S* (upper panel) and *MDM4* (lower panel) expression in B-CLL patient samples. **B**. *MDM4-S/MDM4* ratio in B-CLL patient samples. Ctrl is the normal lymphocyte RNA control. Samples were normalized to Ctrl that was set to 1. \* indicates samples with 17p deletion which spans the p53 locus.](oncotarget-08-25837-g001){#F1}

Generation of Mdm4-S overexpression mouse {#s2_2}
-----------------------------------------

In order to examine a possible pathogenetic role of *MDM4-S* overexpression in B-CLL, we cloned a murine *Mdm4-S* cDNA into the pBSVE6BK vector (Figure [2A](#F2){ref-type="fig"}). This transgene vector harbors the Ig gene VH promoter and the intronic enhancer and has been shown to drive gene expression restricted to the B-cell lineage, thus allowing us to specifically target Mdm4-S expression in the cell of origin of B-CLL \[[@R25]\]. We confirmed the presence of the *Mdm4-S* transgene in tail snip DNA of 4 of 10 founder mice (data not shown). Based on subsequent characterization, we pursued two lines, henceforth called *2MX-S* and *8MX-S*, for germline transmission and follow-up studies.

![Generation and characterization of\
***Mdm4-S*** transgenic mouse. **A**. Design of transgenic mouse Mdm4-S construct. **B**. Real-time PCR showing *Mdm4-S* and *Mdm4* mRNA expression, and the *Mdm4-S/Mdm4* ratio in transgenic mouse spleens. *n* = 3, ±SEM. **C**. WB of protein lysates from transgenic mouse spleens showing Mdm4-S and Mdm4 expression. - and + represent negative and positive controls for Mdm4 expression respectively **D**. Co-IP of Mdm4-S with an anti-p53 antibody. **E**. RT-qPCR for p53 targets in mouse spleens. *n* = 3, ±SEM. WT: wild type, WB: western blot, IP: immunoprecipitation, \#: blank lane, \*: non specific, ns: not significant.](oncotarget-08-25837-g002){#F2}

Characterization of Mdm4-S overexpression mouse lines {#s2_3}
-----------------------------------------------------

As our original strategy targeted overexpression of *Mdm4-S* mRNA in the B-cell lineage, we first examined *Mdm4-S* expression in the spleen (a predominantly B-cell organ) of these mice. Compared to wild type controls, *2MX-S* and *8MX-S* mouse spleens showed 60- and 20-fold higher expression of *Mdm4-S* mRNA, respectively (Figure [2B](#F2){ref-type="fig"}). Next, we analyzed the mRNA expression of full length *Mdm4* and the corresponding *Mdm4-S/Mdm4* ratio in these two mouse lines. The *Mdm4-S/Mdm4* ratio was significantly higher (19x and 13x, respectively) in these mice compared to the wild type controls. Further, we examined the Mdm4-S protein levels in the spleens of these mice. An increased abundance of Mdm4-S protein was detected in the spleens of *2MX-S* and *8MX-S* mice, while no difference in Mdm4 levels was observed across the different mouse genotypes (Figure [2C](#F2){ref-type="fig"}). Of note, no Mdm4-S protein expression was noted in wild type mouse spleens indicating lack of detectable levels of Mdm4-S in normal animal tissues.

Mdm4-S encodes a truncated Mdm4 protein with only the N-terminal p53 binding domain intact \[[@R15]\]. To confirm whether the overexpressed Mdm4-S protein in our transgenic mice similarly binds to endogenous p53, we performed co-immunoprecipitation experiments. We immunoprecipitated protein lysates from spleens of *wild type*, *2MX-S* and *8MX-S* mice with an anti-p53 antibody and subjected it to immunoblotting with anti-Mdm4 antibody (Figure [2D](#F2){ref-type="fig"}). As expected, we could pull down Mdm4-S from 2MX-S and 8MX-S protein lysate with a p53 antibody confirming the interaction between the two proteins, though the interaction appeared much weaker compared to Mdm4 and p53 proteins. We also examined p53 transcriptional activity in the spleens of these transgenic mice (Figure [2E](#F2){ref-type="fig"}). Interestingly, mRNA expression of p53 downstream targets *p21* and *Puma* was slightly lower in *2MX-S* and *8MX-S* mouse spleens compared to their wild type counterpart, but the difference was not statistically significant.

In order to determine whether overexpression of the Mdm4-S variant in B-cells leads to hematological alterations in transgenic mice, we next examined hemograms of *2MX-S* and *8MX-S* mice (Figure [3A](#F3){ref-type="fig"}). No variation in complete blood cell count was observed in 16-20 month old *2MX-S* and *8MX-S* mice when compared to age matched wild-type control mice. In addition, blood smears from the transgenic mice of different ages also failed to reveal any significant morphological or quantitative differences compared to smears obtained from normal controls. No sign of malignant transformation was detected (Figure [3B](#F3){ref-type="fig"}). Next, we proceeded with complete histo-pathological examination of spleens obtained from *2MX-S* and *8MX-S* mice of different ages. Again, no splenomegaly or other obvious signs of disease were noted (Figure [3B](#F3){ref-type="fig"}). Finally, to evaluate whether overexpression of the Mdm4-S variant leads to a B-cell malignant phenotype in mice, we performed flow cytometry to evaluate CD5 and CD19 co-expression on splenocytes. CD5:CD19 double positivity is a characteristic phenotypic feature of B-CLL cells \[[@R26]\]. Remarkably, no differences in double positive cell counts was observed in wild type and transgenic mouse spleens (Figure [3C](#F3){ref-type="fig"}). Of note, for some unknown reasons the percentage of double positive CD5:CD19 cells in *8MX-S* mice was noticeably lower than the wild type controls.

![Overexpression of\
***Mdm4-S*** does not promote B-cell associated malignancy in mice. **A**. Complete CBC analysis of WT (*n* = 4), 2MX-S (*n* = 7) and 8MX-S (*n* = 11) transgenic mice. ±SEM. **B**. Top panel- Representative peripheral blood smear slides from WT, 2MX-S and 8MX-S mice. 100x magnification. Bottom panel- Representative Hematoxylin and eosin stained sections of spleens from WT, 2MX-S and 8MX-S mice. 40x magnification. **C**. Flow cytometry analysis for CD5 and CD19 double positive cells in splenocytes generated from WT, 2MX-S and 8MX-S mice. *n* = 3, ±SEM. WT: wild type.](oncotarget-08-25837-g003){#F3}

Tumorigenic profile and survival of Mdm4-S overexpressing transgenic mouse lines {#s2_4}
--------------------------------------------------------------------------------

To evaluate the physiological impact of Mdm4-S overexpression in mice of both transgenic lines, we generated cohorts of *2MX-S* and *8MX-S* mice and monitored them for tumor development and overall survival (Figure [4A](#F4){ref-type="fig"}). Surprisingly, none of the transgenic mice overexpressing Mdm4-S developed a B-cell malignant phenotype. In addition, no apparent change in overall survival was noted in Mdm4-S overexpressing mouse lines. Most mice were sacrificed at the end of study (i.e. 600 days).

![Mdm4-S overexpression does not cooperate with other oncogenic insults\
**A**. Kaplan-Meier survival curve of 2MX-S and 8MX-S transgenic mouse lines. **B**. Kaplan-Meier survival curve of *2MX-S:Mdm4^+/Δ2^* and 8MX-S:*Mdm4^+/Δ2^* mouse lines. **C**. Kaplan-Meier survival curve of *TCL1*, *2MX-S:TCL1* and *8MX-S:TCL1* mice.](oncotarget-08-25837-g004){#F4}

Recent studies have reported that increased splicing at the *MDM4* locus counters the expression of full length Mdm4 \[[@R17], [@R18]\]. In addition, an increase in *MDM4-S/MDM4* ratio has been proposed as a marker of poor prognosis in different human cancers \[[@R17]\]. In order to test whether an increase in *Mdm4-S* in conjunction with a corresponding decrease in full length *Mdm4* promotes B-cell malignancy, we crossed Mdm4-S transgenic mice to *Mdm4^Δ2^* mice. *Mdm4^Δ2^* is a null allele previously generated in our lab \[[@R27]\]. We monitored a cohort of *2MX-S:Mdm4^+/Δ2^* and *8MX-S: Mdm4^+/Δ2^* mice for tumor development. Interestingly, even with genetically half gene dosage of the full length *Mdm4*, *2MX-S:Mdm4^+/Δ2^* and *8MX-S:Mdm4^+/Δ2^* mice did not develop any B-cell malignant phenotype and lived a normal life span (Figure [4B](#F4){ref-type="fig"}).

Lastly, we tested whether *Mdm4-S* overexpression cooperates with other oncogenes in tumorigenesis. To that end, we crossed *Mdm4-S* mice with *Eμ-TCL1* transgenic mice, a prototypical B-CLL mouse model expressing the T cell leukemia-1(*TCL1*) transgene in B-cells that displays similar clinical and therapeutic response properties to human B-CLL \[[@R28]\]. We generated a cohort of *2MX-S*:*TCL1*, and *8MX-S*:*TCL1* mice and investigated whether cooperation of these two genetic events leads to earlier tumorigenesis and shorter survival in these compound mice (Figure [4C](#F4){ref-type="fig"}). Intriguingly, genetic combination of these two events did not alter the B-CLL latency or the overall survival of these mice. Failure to exacerbate the disease profile ruled out cooperativity between these two oncogenic insults.

Mdm4-S overexpression is a consequence of tumorigenesis {#s2_5}
-------------------------------------------------------

Finally, given the lack of an overt malignant phenotype, we investigated whether overexpression of *Mdm4-S* is a consequence rather than a cause of tumorigenic events. To that end, we isolated spleens from 3 week old *p53^+/+^*, p53^−/−^, and *p53^R172H/H^* (inheriting 2 copies of the p53R172H hotspot mutation) pre-tumorigenic mice. Separately, we also collected different types of tumors (lymphoma and osteosarcoma) that originated in *p53 ^+\ /\ −^*, *p53 ^−/−^*, and *p53^R172H/H^* mice. We isolated RNA from these normal pre-tumorigenic spleens and mouse tumors and performed RT-PCR analysis to compare the *Mdm4-S* expression in these biological samples (Figure [5A](#F5){ref-type="fig"}). Notably, we did not observe high levels of *Mdm4-S* mRNA in the spleens of pre-tumor mice of any genotype (Figure [5A](#F5){ref-type="fig"}, lanes 1-9). However, the *Mdm4-S* mRNA was prominently expressed in all 16 mouse tumor samples examined (Figure [5A](#F5){ref-type="fig"}, lanes 10-25). Next, we tested whether splicing of other genes is also altered in the above mouse spleens and tumor samples. To that end we examined the expression of *Fibroblast Growth Factor Receptor 1* (*Fgfr1*) mRNA in these biological samples. *Fgfr1* produces a splice variant by exon 3 skipping in tumors. Similar to the *Mdm4-S* expression, very little expression of *Fgfr1* splice variant was observed in pre-tumorigenic spleens (Figure [5](#F5){ref-type="fig"}). In contrast, a noticeable expression of *Fgfr1* splice variant was evident in all the murine tumor samples.

![Aberrant gene splicing is a consequence of tumorigenesis\
**A**. RT-PCR analysis to show *Mdm4-S* and *Fgfr1* splice variant expression in normal spleens (lane 1-9) and tumors (lane 10-25) from *wild type*, *p53^+/\ −^*, *p53 ^−/−^* and *p53^R172H/H^* mice. *Gapdh* is used as a control. **B**. Real time PCR analysis for *Mdm4-S* expression in mouse normal bladder (NB), non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) samples.](oncotarget-08-25837-g005){#F5}

Finally, to rule out the possibility that pre-existing genomic instability in the *p53^+/−^*, *p53^−/−^*, and *p53^R172H/H^* mice promoted splicing events in the above experiment, we also screened for *Mdm4-S* expression in non-muscle invasive and muscle invasive bladder cancer (NMIBC and MIBC) samples that originated in wild type mice after treatment with N-Butyl-N-(4-hydroxybutyl)nitrosamine (*BBN*), a urothelial carcinogen. Again, real time PCR analysis indicated that increased *Mdm4-S* expression was confined to tumor samples (Figure [5B](#F5){ref-type="fig"}). Relatively higher *Mdm4-S* mRNA levels were noted in MIBC samples compared to NMIBC samples, though this was not statistically significant. Altogether, these results highlight that expression of gene splice variants is a phenomenon associated with tumorigenesis but not necessarily the cause of it.

DISCUSSION {#s3}
==========

Disruption of the p53 pathway by overexpression of MDM4 is a common theme in many different types of human cancers. Recent studies have shown that the *MDM4* locus produces multiple splice variants in tumors as well as in culture cells that are exposed to stress conditions \[[@R15]\]. In particular, one such splice variant *MDM4-S*, generated by exon 6 skipping correlates with poor prognosis in different types of cancers \[[@R11], [@R17], [@R20]\]. However, in the absence of prospective studies, it is not clear whether *MDM4-S* overexpression is a cause or consequence of tumorigenesis.

Following our initial observations that *MDM4-S* transcript is overexpressed in B-CLL and to directly address this question, we generated a transgenic mouse in which *Mdm4-S* overexpression was restricted to the B-cell lineage. This strategy allowed us to avoid the embryonic death fate and directly address the significance of *Mdm4-S* overexpression in B-cell associated tumorigenesis. Notably, we validated *Mdm4-S* expression in spleens of the transgenic mice and also confirmed the interaction between transgene derived Mdm4-S and the endogenous p53 protein. A relatively weak p53-Mdm4-S interaction along with slight decrease in basal p53 transcriptional activity was observed. Nonetheless, overexpression of *Mdm4-S* variant in the B-cell lineage did not result in a malignant phenotype thereby ruling out untoward suppression of the p53 pathway.

Recent studies indicate that *MDM4-S* transcripts regulate the abundance of MDM4 protein and that the *MDM4-S/MDM4* ratio correlates with tumor aggressiveness \[[@R17]\]. In order to test this we modulated the *Mdm4-S/Mdm4* ratio by crossing *Mdm4-S* transgenic mice with *Mdm4^Δ2^* mice. Surprisingly, decreasing the levels of full-length Mdm4 by 50% and thereby increasing the *Mdm4-S/Mdm4* ratio also failed to promote B-cell linked tumorigenesis. These results are similar to the previous report that showed decrease in *Mdm4-S/Mdm4* ratio had little effect on adult mouse tissues \[[@R24]\]. Furthermore, genetic crosses with a prototypical B-CLL mouse model also showed that Mdm4-S expression does not cooperate with other oncogenic insults such as *TCL1* transgene expression to alter B-cell tumor latency in mice. Altogether, these results argue against the speculated role of *Mdm4-S* expression as an oncogene in B-cell lymphomagenesis.

Finally, it has been proposed that *MDM4-S* overexpression can serve as an effective biomarker for p53 pathway attenuation in cancers than p53 gene mutation itself \[[@R17]\]. This was clearly correlative in osteosarcoma and breast cancers \[[@R17], [@R21]\]. However, we did not observe any correlation between *MDM4-S* expression and p53 mutation status in the human B-CLL samples (Figure [1](#F1){ref-type="fig"}). Of note, we did not analyze expression levels of Mdm2 or other p53 inhibitors and therefore cannot rule out p53 pathway attenuation by other mechanisms. Importantly, prominent *Mdm4-S* expression was restricted to mouse tumors with genetic loss of p53 function and no expression was observed in normal mouse spleens (Figure [5](#F5){ref-type="fig"}). Moreover, Mdm4-S protein was not detected in mouse tumors that exhibited high levels of *Mdm4-S* mRNA (data not shown). This is in agreement with the recent reports that suggest that the endogenous *Mdm4-S* transcript is susceptible to nonsense mediated decay \[[@R18], [@R24], [@R29]\].

Nonetheless, the expression of splice variant of *Mdm4* and one other gene was clearly evident in a range of mouse tumor samples. Previously, genome-wide studies have revealed that large scale alterations in alternative splicing are associated with tumorigenesis \[[@R30], [@R31]\] and mutations in *SF3B1*, a core component of spliceosome machinery correlate with disease aggressiveness and shorter survival in CLL \[[@R32]\]. Furthermore, it has been proposed that *MDM4* alternative splicing serves as a key sensor of defects in the constitutive spliceosomal machinery that result in activation of the p53 response \[[@R29]\]. In keeping with this function, it is no surprise that 1). *p53* is commonly lost or mutated due to selective pressure in tumors with expression of *MDM4-S* and 2). *MDM4-S* expression correlates with tumor aggressiveness and poor prognosis in different human cancers \[[@R17]\]. The relevance of our study is that we have demonstrated that overexpression of *Mdm4-S* in B-cells is not oncogenic *per se* and is rather a consequence of tumorigenesis, at least in CLL. Thus, our *in vivo* study supports the idea of using *Mdm4-S* mRNA levels as a possible biomarker but cautions against over-interpreting splicing data for therapeutic purposes.

MATERIALS AND METHODS {#s4}
=====================

Human B-CLL patient sample collection {#s4_1}
-------------------------------------

Human samples were obtained from patients with newly diagnosed B-CLL prior to receiving standard frontline therapy with the fludarabine, cyclophosphamide, and rituximab (i.e. FCR regimen). Samples were obtained from the Department of Leukemia Tissue Bank at MD Anderson Cancer Center where they had been stored after being acquired during routine diagnostic assessments in accordance with the regulations and protocols approved by the MD Anderson Cancer Center Investigational Review Board. Signed informed consent was obtained from all patients and research was conducted in accordance with the Declaration of Helsinki. Samples were examined by a hematopathologist and graded per Rai stage. ZAP70 expression and IgVH mutation status as prognostic markers was confirmed. Chromosome 12 trisomy, 13q deletion, ATM deletion and p53 deletion were assessed by fluorescence *in situ* hybridization (FISH) analysis. Mdm2 SNP309 status was also determined.

Generation of transgenic *Mdm4-S* mice {#s4_2}
--------------------------------------

Mouse *Mdm4-S* cDNA was cloned as an EcoRV-Sal1 fragment into the pBSVE6BK vector. Linearized vector was injected into blastocysts to generate chimeric mice by the Genetically Engineered Mouse Facility at the MD Anderson Cancer Center. DNA from mouse tail snips was PCR amplified with vector specific forward primer (acccagatgtcccttcttctccag) and Mdm4-S specific reverse primer (gactcgagtcagttctttttctgggattg) to confirm the presence of the transgene. All mouse studies were approved by MD Anderson Cancer Center IACUC. *TCL1* mice were a gift from Dr. Croce (Ohio State University, Columbus, OH). *Mdm4^Δ2^* mice were previously generated in our lab \[[@R27]\].

RNA isolation and real time PCR {#s4_3}
-------------------------------

RNA was isolated from mouse spleen or human B-CLL patient lymphocytes using TRIzol (Thermo Fisher Scientific). After DNase1 treatment and phenol-chloroform extraction, RNA was precipitated and suspended in DNase/RNase free water. One microgram of RNA was used for first strand synthesis (First-Strand cDNA Synthesis Kit, GE Life Sciences). Real time PCR was carried out as previously described \[[@R6]\]. Real time PCR conditions and primers for amplifying *MDM4-S*, *MDM4* and *GAPDH* from human B-CLL samples were originally described by Bartel et al \[[@R11]\]. Primers used for RT-qPCR for amplifying *Mdm4-S* (for-tgtgaaagatccaagccctct, rev-tgttgcaccgtgctgtgtta), *Mdm4* (for-ggaaaagcccaggtttgacc, rev-gccaaatccaaaaatcccact) and *Rplp0* (for-ccctgaagtgctcgacatca, rev-tgcggacaccctccagaa).

Primers used for semi-quantitative RT-PCR for amplifying mouse- *Mdm4-S* (for-tgtggtggagatcttttggg and rev-tcagttctttttctgggattgg), *Fgfr1* (for-gccttgttaccaacctctaac and rev-gaaccttgtagcctccaattc) and *Gapdh* (for-aggttgtctcctgcgacttca and rev-ggtggtccagggtttcttactc).

Western blotting and immunoprecipitation {#s4_4}
----------------------------------------

Mouse spleen were lysed in NP-40 buffer and 100μg of protein lysate was resolved on 4-15% gradient gels (BioRad) and Immunoblotted with either anti-p53 (CM5, Vector Biolabs, 1:1000) or anti-Mdm4 (MX-82, Calbiochem, 1:500) or anti-actin (AC15, Sigma, 1:5000) antibodies. For IP, 1 mg of protein lysate was pulled down with anti-p53 antibody (CM5) and immunoblotted with either Mdm4 antibody (MX-82, Calbiochem, 1:500) or p53 antibody (FL393, Santa Cruz biotechnology, 1:500). 10% of protein lysate was used as input.

CBC analysis and flow cytometry {#s4_5}
-------------------------------

Blood collected from heart puncture was analyzed by Dept. of Veterinary Medicine hematology core at MD Anderson Cancer Center. Blood smear slides were stained with Hema-3 fixative (Fisher Healthcare) and microscopically analyzed by a hematopathologist. Splenocytes isolated from wild type, 2MX-S and 8MX-S mouse spleens were treated with RBC lysis buffer and labelled with CD19-FITC (BD Pharmingen) and CD5-PE (eBiosciences) antibodies in binding buffer. Flow analysis was carried out by flow cytometry core at MD Anderson Cancer Center.

We are thankful to Ms. Gilda Chau for mouse genotyping help. Mice were made by the GEM Facility at The MDACC funded by cancer center support grant (CA16672).
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